Blood test guides fight against lung cancer return
NCT ID NCT04367311
Summary
This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy after lung cancer surgery can better prevent the cancer from coming back. It involves 100 adults who have had surgery for certain stages of non-small cell lung cancer and still have signs of cancer DNA in their blood. Researchers will track if this combination treatment clears the cancer DNA from the blood, which may predict long-term success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
New York University Clinical Cancer Center
New York, New York, 10016, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Summit Health
Berkeley Heights, New Jersey, 07922, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.